Target intelligence / Profile preview

Excipient

Molecular classification
Other
01

Overview

An excipient is defined as any substance, other than the active pharmaceutical ingredient (API), that is intentionally included in a drug delivery system to facilitate manufacturing, protect the API, or enhance product performance (NIH) [2, 4]. These substances serve diverse functional roles, including acting as binders, disintegrants, lubricants, and preservatives, which are essential for creating stable and effective dosage forms such as tablets or injections (Wikipedia) [6]. While historically classified as pharmacologically inert, modern research has demonstrated that many excipients possess bioactivity and can influence a drug's pharmacokinetics by modulating transporters or metabolic enzymes (PMC) [10]. Excipients are critical for improving the solubility and bioavailability of poorly water-soluble drugs and can be engineered for targeted or controlled drug release (ScienceDirect) [1, 5]. Despite their biological influence on drug absorption and safety, they are not considered therapeutic targets in the context of drug discovery; rather, they are strategic components of the pharmaceutical formulation intended to optimize the delivery of the primary therapeutic agent (Colorcon) [11]. Biopharmaceutical analysts must consider excipient selection carefully, as interactions between these 'inactive' ingredients and the biological milieu can impact the overall clinical efficacy and safety profile of a medication (MDPI) [7, 8].

Other names
Inactive ingredientPharmaceutical aidAdditiveVehicleCarrier
02

Mechanism of action

Not applicable; excipients are auxiliary substances in drug formulations and do not serve as therapeutic targets for other drugs.

03

Biological functions

Drug delivery facilitationStability enhancementBioavailability modulationPreservationBulking
04

Disease associations

Other
05

Safety considerations

Allergic reactions (e.g., to dyes or preservatives)Intolerance (e.g., lactose or gluten sensitivity)Incompatibility with active pharmaceutical ingredients (APIs)Metabolic interference (e.g., inhibition of CYP450 enzymes or P-glycoprotein)Toxicity at high concentrations

Beyond the preview

Go deeper on Excipient.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Excipient.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call